Neurotherapeutics

, Volume 5, Issue 2, pp 270–280

Treatment of Parkinson’s disease with trophic factors

Restorative Approach Trophic Factors for Parkinson’s Disease

Summary

Trophic factors are proteins that support and protect subpopulations of cells. A number have been reported to act on dopaminergic neurons in vitro and in vivo, making them potential therapeutic candidates for Parkinson’s disease. All of these candidate factors protect dopaminergic neurons if given prior to, or with, selective neurotoxins. Fewer trophic factors, primarily glial-derived neurotrophic factor (GDNF) and its relative, neurturin (NRTN; also known as NTN), have been shown to restore function in damaged dopamine neurons after the acute effects of neurotoxins have subsided. A major barrier to clinical translation has been delivery. GDNF delivered by intracerebroventricular injection in patients was ineffective, probably because GDNF did not reach the target, the putamen, and intraputaminal infusion was ineffective, probably because of limited distribution within the putamen. A randomized clinical trial with gene therapy for NRTN is underway, in an attempt to overcome these problems with targeting and distribution. Other strategies are available to induce trophic effects in the CNS, but have not yet been the focus of human research. To date, clinical trials have focused on restoration of function (i.e., improvement of parkinsonism). Protection (i.e., slowing or halting disease progression and functional decline) might be a more robust effect of trophic agents. Laboratory research points to their effectiveness in protecting neurons and even restoring dopaminergic function after a monophasic neurotoxic insult. Utility for such compounds in patients with Parkinson’s disease and ongoing loss of dopaminergic neurons remains to be proven.

Key Words

Parkinson’s disease trophic factors clinical trials glial-derived neurotrophic factors neurturin 

References

  1. 1.
    Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004;351: 1403–1408.PubMedGoogle Scholar
  2. 2.
    Cohen S, Levi-Montalcini R, Hamburger V. A nerve growth-stimulating factor isolated from sarcomas 37 and 180. Proc Natl Acad Sci U S A 1954;40: 1014–1018.PubMedGoogle Scholar
  3. 3.
    Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996;8: 666–676.PubMedGoogle Scholar
  4. 4.
    Butte MJ. Neurotrophic factor structures reveal clues to evolution, binding, specificity, and receptor activation. Cell Mol Life Sci 2001;58: 1003–1013.PubMedGoogle Scholar
  5. 5.
    Maisonpierre PC, Belluscio L, Friedman B, et al. NT-3, BDNF, and NGF in the developing rat nervous system: parallel as well as reciprocal patterns of expression. Neuron 1990;5: 501–509.PubMedGoogle Scholar
  6. 6.
    Maisonpierre PC, Le Beau MM, Espinosa R III, et al. Human and rat brain-derived neurotrophic factor and neurotrophin-3: gene structures, distributions, and chromosomal localizations. Genomics 1991;10: 558–568.PubMedGoogle Scholar
  7. 7.
    Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: A glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260: 1130–1132.PubMedGoogle Scholar
  8. 8.
    Bespalov MM, Saarma M. GDNF family receptor complexes are emerging drug targets. Trends Pharmacol Sci 2007;28: 68–74.PubMedGoogle Scholar
  9. 9.
    Petrova P, Raibekas A, Pevsner J, et al. MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons. J Mol Neurosci 2003;20: 173–188.PubMedGoogle Scholar
  10. 10.
    Lindholm P, Voutilainen MH, Lauren J, et al. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 2007;448: 73–77.PubMedGoogle Scholar
  11. 11.
    Shults CW. Neurotrophic factors. In: Watts RL, Koller WC, editors. Movement disorders: neurologic principles and practice. 2nd ed. New York: McGraw-Hill, 2004;131–142.Google Scholar
  12. 12.
    Fontan A, Rojo A, Sanchez-Pernaute R, et al. Effects of fibroblast growth factor and glial-derived neurotrophic factor on akinesia, F-DOPA uptake and dopamine cells in parkinsonian primates. Parkinsonism Relat Disord 2002;8: 311–323.PubMedGoogle Scholar
  13. 13.
    Levi-Montalcini R. The nerve growth factor 35 years later. Science 1987;237: 1154–1162.PubMedGoogle Scholar
  14. 14.
    Heerssen HM, Segal RA. Location, location, location: a spatial view of neurotrophin signal transduction. Trends Neurosci 2002; 25: 160–165.PubMedGoogle Scholar
  15. 15.
    Kohara K, Kitamura A, Morishima M, Tsumoto T. Activity-dependent transfer of brain-derived neurotrophic factor to postsynaptic neurons. Science 2001;291: 2419–2423.PubMedGoogle Scholar
  16. 16.
    Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S. Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: evidence for anterograde axonal transport. J Neurosci 1997;17: 2295–2313.PubMedGoogle Scholar
  17. 17.
    Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J 2003;17: 944–946.PubMedGoogle Scholar
  18. 18.
    Baquet ZC, Bickford PC, Jones KR. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 2005;25: 6251–6259.PubMedGoogle Scholar
  19. 19.
    Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 1994;342: 321–334.PubMedGoogle Scholar
  20. 20.
    Zhang HT, Li LY, Zou XL, et al. Immunohistochemical distribution of NGF, BDNF, NT-3, and NT-4 in adult rhesus monkey brains. J Histochem Cytochem 2007;55: 1–19.PubMedGoogle Scholar
  21. 21.
    Mogi M, Togari A, Kondo T, et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson’s disease. Neurosci Lett 1999;270: 45–48.PubMedGoogle Scholar
  22. 22.
    Howells DW, Porritt MJ, Wong JY, et al. Reduced BDNF mRNA expression in the Parkinson’s disease substantia nigra. Exp Neurol 2000;166: 127–135.PubMedGoogle Scholar
  23. 23.
    Hyman C, Hofer M, Barde YA, et al. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991;350: 230–232.PubMedGoogle Scholar
  24. 24.
    Spina MB, Hyman C, Squinto S, Lindsay RM. Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann N Y Acad Sci 1992;648: 348–350.PubMedGoogle Scholar
  25. 25.
    Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent l-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci U S A 1994;91: 5104–5108.PubMedGoogle Scholar
  26. 26.
    Shults CW, Kimber T, Altai- CA. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. Neuroreport 1995; 6: 1109–1112.PubMedGoogle Scholar
  27. 27.
    von Bohlen und Halbach O, Minichiello L, Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of accumulation of α-synuclein in the substantia nigra. FASEB J 1919;1740–1742.Google Scholar
  28. 28.
    Karamohamed S, Latourelle JC, Racette BA, et al. BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study. Neurology 2005;65: 1823–1825.PubMedGoogle Scholar
  29. 29.
    Granholm AC, Reyland M, Albeck D, et al. Glial cell line-derived neurotrophic factor is essential for postnatal survival of midbrain dopamine neurons. J Neurosci 2000;20: 3182–3190.PubMedGoogle Scholar
  30. 30.
    Oo TF, Ries V, Cho J, Kholodilov N, Burke RE. Anatomical basis of glial cell line-derived neurotrophic factor expression in the striatum and related basal ganglia during postnatal development of the rat. J Comp Neurol 2005;484: 57–67.PubMedGoogle Scholar
  31. 31.
    Mogi M, Togari A, Kondo T, et al. Glial cell line-derived neurotrophic factor in the substantia nigra from control and parkinsonian brains. Neurosci Lett 2001;300: 179–181.PubMedGoogle Scholar
  32. 32.
    Bäckman CM, Shan L, Zhang YJ, et al. Gene expression patterns for GDNF and its receptors in the human putamen affected by Parkinson’s disease: a real-time PCR study. Mol Cell Endocrinol 2006;252: 160–166.PubMedGoogle Scholar
  33. 33.
    Tomac A, Lindqvist E, Lin LF, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373: 335–339.PubMedGoogle Scholar
  34. 34.
    Kearns CM, Gash DM. GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 1995;672: 104–111.PubMedGoogle Scholar
  35. 35.
    Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 2004;7: 105–110.PubMedGoogle Scholar
  36. 36.
    Kirik D, Rosenblad C, Björklund A. Reservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000; 12: 3871–3882.PubMedGoogle Scholar
  37. 37.
    Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease. Science 2000;290: 767–773.PubMedGoogle Scholar
  38. 38.
    Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002;177: 461–474.PubMedGoogle Scholar
  39. 39.
    Eslamboli A, Georgievska B, Ridley RM, et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson’s disease. J Neurosci 2005;25: 769–777.PubMedGoogle Scholar
  40. 40.
    Kirik D, Georgievska B, Rosenblad C, Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson’s disease. Eur J Neurosci 2001; 13: 1589–1599.PubMedGoogle Scholar
  41. 41.
    Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380: 252–255.PubMedGoogle Scholar
  42. 42.
    Zhang Z, Miyoshi Y, Lapchak PA, et al. Dose response to intraventricular glial cell line-derived neurotrophic factor administration in parkinsonian monkeys. J Pharmacol Exp Ther 1997;282: 1396–1401.PubMedGoogle Scholar
  43. 43.
    Grondin R, Zhang Z, Yi A, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys [Comment in: Brain 2002;125:2149–2151]. Brain 2002;125: 2191–2201.PubMedGoogle Scholar
  44. 44.
    Yang F, Feng L, Zheng F, et al. GDNF acutely modulates excitability and A-type K+ channels in midbrain dopaminergic neurons. Nat Neurosci 2001;4: 1071–1078.PubMedGoogle Scholar
  45. 45.
    Hebert MA, Van Horne CG, Hoffer BJ, Gerhardt GA. Functional effects of GDNF in normal rat striatum: presynaptic studies using in vivo electrochemistry and microdialysis. J Pharmacol Exp Ther 1996;279: 1181–1190.PubMedGoogle Scholar
  46. 46.
    Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384: 467–470.PubMedGoogle Scholar
  47. 47.
    Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998;18: 4929–4937.PubMedGoogle Scholar
  48. 48.
    Hoane MR, Gulwadi AG, Morrison S, Hovanesian G, Lindner MD, Tao W. Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 1999; 160: 235–243.PubMedGoogle Scholar
  49. 49.
    Li H, He Z, Su T, et al. Protective action of recombinant neurturin on dopaminergic neurons in substantia nigra in a rhesus monkey model of Parkinson’s disease. Neurol Res 2003;25: 263–267.PubMedGoogle Scholar
  50. 50.
    Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60: 706–715.PubMedGoogle Scholar
  51. 51.
    Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson’s disease after administration into the striatum or the lateral ventricle. Eur J Neurosci 1999;11: 1554–1566.PubMedGoogle Scholar
  52. 52.
    Oiwa Y, Yoshimura R, Nakai K, Itakura T. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson’s disease. Brain Res 2002;947: 271–283.PubMedGoogle Scholar
  53. 53.
    Tseng JL, Bruhn SL, Zurn AD, Aebischer P. Neurturin protects dopaminergic neurons following medial forebrain bundle axotomy. Neuroreport 1998;9: 1817–1822.PubMedGoogle Scholar
  54. 54.
    Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 2007;22: 1124–1132.PubMedGoogle Scholar
  55. 55.
    Langsten JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59: 591–596.Google Scholar
  56. 56.
    Beck M, Flachenecker P, Magnus T, et al. Autonomic dysfunction in ALS: a preliminary study on the effects of intrathecal BDNF. Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6: 100–103.PubMedGoogle Scholar
  57. 57.
    Fischer W, Wictorin K, Björklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 1987;329: 65–68.PubMedGoogle Scholar
  58. 58.
    Gash DM, Zhang Z, Cass WA, et al. Morphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys. J Comp Neurol 1995;363: 345–358.PubMedGoogle Scholar
  59. 59.
    Oiwa Y, Nakai K, Itakura T. Histological effects of intraputaminal infusion of glial cell line-derived neurotrophic factor in Parkinson disease model macaque monkeys. Neurol Med Chir (Tokyo) 2006;46: 267–275; discussion 275–276.Google Scholar
  60. 60.
    Ai Y, Markesbery W, Zhang Z, et al. Intraputamenal infusion of GDNF in aged rhesus monkeys: distribution and dopaminergic effects. J Comp Neurol 2003;461: 250–261.PubMedGoogle Scholar
  61. 61.
    Laske DW, Morrison PF, Lieberman DM, et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997;87: 586–594.PubMedGoogle Scholar
  62. 62.
    Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007;106: 614–620.PubMedGoogle Scholar
  63. 63.
    Hadaczek P, Kohutnicka M, Krauze MT, et al. Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 2006;17: 291–302.PubMedGoogle Scholar
  64. 64.
    Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood—brain barrier for the treatment of patients with malignant brain tumors. Cancer 2000; 88: 637–647.PubMedGoogle Scholar
  65. 65.
    Muldoon LL, Nilaver G, Kroll RA, et al. Comparison of intracerebral inoculation and osmotic blood—brain barrier disruption for delivery of adenovirus, herpesvirus, and iron oxide particles to normal rat brain. Am J Pathol 1995;147: 1840–1851.PubMedGoogle Scholar
  66. 66.
    Behrstock S, Ebert A, McHugh J, et al. Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates. Gene Ther 2006; 13: 379–388.PubMedGoogle Scholar
  67. 67.
    Pardridge WM. Targeting neurotherapeutic agents through the blood—brain barrier. Arch Neurol 2002;59: 35–40.PubMedGoogle Scholar
  68. 68.
    Wu D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A 1999; 96: 254–259.PubMedGoogle Scholar
  69. 69.
    Juillerat-Jeanneret L, Schmitt F. Chemical modification of therapeutic drugs or drug vector systems to achieve targeted therapy: looking for the grail. Med Res Rev 2007;27: 574–590.PubMedGoogle Scholar
  70. 70.
    Guan J, Krishnamurthi R, Waldvogel HJ, Faull RL, Clark R, Gluckman P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 2000;859: 286–292.PubMedGoogle Scholar
  71. 71.
    Peleshok J, Saragovi HU. Functional mimetics of neurotrophins and their receptors. Biochem Soc Trans 2006;34: 612–617.PubMedGoogle Scholar
  72. 72.
    Tokugawa K, Yamamoto K, Nishiguchi M, et al. XIB4035, a novel nonpeptidyl small molecule agonist for GFRα-1. Neurochem Int 2003;42: 81–86.PubMedGoogle Scholar
  73. 73.
    Ries V, Henchcliffe C, Kareva T, et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson’s disease. Proc Natl Acad Sci U S A 2006;103: 18757–18762.PubMedGoogle Scholar
  74. 74.
    He DY, Ron D. Autoregulation of glial cell line-derived neurotrophic factor expression: implications for the long-lasting actions of the anti-addiction drug, ibogaine. FASEB J 2006;20: 2420–2422.PubMedGoogle Scholar
  75. 75.
    Malberg JE, Blendy JA. Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci 2005;26: 631–638.PubMedGoogle Scholar
  76. 76.
    Adlard PA, Perreau VM, Engesser-Cesar C, Cotman CW. The timecourse of induction of brain-derived neurotrophic factor mRNA and protein in the rat hippocampus following voluntary exercise. Neurosci Lett 2004;363: 43–48.PubMedGoogle Scholar
  77. 77.
    Cohen AD, Tillerson JL, Smith AD, Schallert T, Zigmond MJ. Neuroprotective effects of prior limb use in 6-hydroxydopamine-treated rats: possible role of GDNF. J Neurochem 2003;85: 299–305.PubMedGoogle Scholar
  78. 78.
    Smith AD, Zigmond MJ. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 2003;184: 31–39.PubMedGoogle Scholar
  79. 79.
    Nutt JG, Burchiel KJ, Cornelia CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003;60: 69–73.PubMedGoogle Scholar
  80. 80.
    Kordower JH, Palfi S, Chen E-Y, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson’s disease. Ann Neurol 1999; 46: 419–424.PubMedGoogle Scholar
  81. 81.
    Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9: 589–595.PubMedGoogle Scholar
  82. 82.
    Gill SS, Patel NK, Hotton GR, et al. Addendum: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2006;12: 479.Google Scholar
  83. 83.
    Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS. Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 2005;57: 298–302.PubMedGoogle Scholar
  84. 84.
    Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease [Erratum in: Ann Neurol 2006;60:747]. Ann Neurol 2006;59: 459–466.PubMedGoogle Scholar
  85. 85.
    Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson’s disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 2007;27: 620–627.PubMedGoogle Scholar
  86. 86.
    Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005; 102: 216–222.PubMedGoogle Scholar
  87. 87.
    Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 2007;106: 614–620.PubMedGoogle Scholar
  88. 88.
    Morrison PF, Lonser RR, Oldfield EH. Convective delivery of glial cell line-derived neurotrophic factor in the human putamen. J Neurosurg 2007;107: 74–83.PubMedGoogle Scholar
  89. 89.
    Salvatore MF, Ai Y, Fischer B, et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006;202: 497–505.PubMedGoogle Scholar
  90. 90.
    Hovland DN Jr, Boyd RB, Butt MT, et al. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol 2007;35: 1013–1029.PubMedGoogle Scholar
  91. 91.
    Chebrolu H, Slevin JT, Gash DA, et al. MRI volumetric and intensity analysis of the cerebellum in Parkinson’s disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol 2006;198: 450–456.PubMedGoogle Scholar
  92. 92.
    Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 2005; 11: 703–704.PubMedGoogle Scholar
  93. 93.
    Hutchinson M, Gumey S, Newson R. GDNF in Parkinson disease: an object lesson in the tyranny of type II. J Neurosci Methods 2007;163: 190–192.PubMedGoogle Scholar
  94. 94.
    Matcham J, McDermott MP, Lang AE. GDNF in Parkinson’s disease: the perils of post-hoc power. J Neurosci Methods 2007; 163: 193–196.PubMedGoogle Scholar
  95. 95.
    McRae C, Cherin E, Yamazaki TG, et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial [Erratum in: Arch Gen Psychiatry 2004;61:627]. Arch Gen Psychiatry 2004;61: 412–420.PubMedGoogle Scholar
  96. 96.
    Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langsten JW. Crossroads in GDNF therapy for Parkinson’s disease. Mov Disord 2006;21: 136–141.PubMedGoogle Scholar
  97. 97.
    Zaiss AK, Muruve DA. Immune responses to adeno-associated virus vectors. Curr Gene Ther 2005;5: 323–331.PubMedGoogle Scholar
  98. 98.
    Kwon I, Schaffer DV. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res 2007 Sep 1 [Epub ahead of print].Google Scholar
  99. 99.
    Puskovic V, Wolfe D, Wechuck J, et al. HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther 2006;14: 710–715.PubMedGoogle Scholar
  100. 100.
    Xue YQ, Zhao LR, Guo WP, Duan WM. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson’s disease. Neuroscience 2007;146: 1245–1258.PubMedGoogle Scholar
  101. 101.
    Reglodi D, Tamás A, Lubics A, Szalontay L, Lengvári I. Morphological and functional effects of PACAP in 6-hydroxydopamine-induced lesion of the substantia nigra in rats. Regul Pept 2004;123: 85–94.PubMedGoogle Scholar
  102. 102.
    Akerud P, Holm PC, Castelo-Branco G, Sousa K, Rodriguez FJ, Arenas E. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson’s disease. Mol Cell Neurosci 2002;21: 205–222.PubMedGoogle Scholar
  103. 103.
    Krishnamurthi R, Stott S, Maingay M, et al. N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport 2004;15: 1601–1604.PubMedGoogle Scholar
  104. 104.
    Shults CW, Ray J, Tsuboi K, Gage FH. Fibroblast growth factor-2-producing fibroblasts protect the nigrostriatal dopaminergic system from 6-hydroxydopamine. Brain Res 2000;883: 192–204.PubMedGoogle Scholar

Copyright information

© The American Society for Experimental NeuroTherapeutics, Inc. 2008

Authors and Affiliations

  1. 1.Parkinson’s Disease Research, Educational and Clinical Center (PADRECC), Portland Veteran’s Administration Medical Center, and Department of NeurologyOregon Health Sciences UniversityPortland

Personalised recommendations